No Data
Achieved revenue of 0.13 billion yuan in 2024, with multiple milestones in the R&D pipeline being突破.
Shanghai, March 18, 2025 /PR Newswire/ -- On March 17, 2025, Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceutical" 688373.SH) released its annual report for 2024. In 2024, the company achieved revenue of 0.13 billion yuan, a year-on-year increase of 43.51%. The commercialization process of the core product, Contizolam Tablets, is steadily advancing, and the pipeline under research has also achieved multiple milestone breakthroughs. The commercialization potential of the core product, Contizolam Tablets, continues to be released. As the first self-developed and commercialized new-generation oxazolidinone antibacterial drug of Mengke Pharmaceutical, Contizolam Tablets.
Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Report
Mengke Pharmaceutical: Summary of the 2024 Annual Report of Shanghai Mengke Pharmaceutical Co., Ltd.
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Shanghai Mengke Pharmaceutical Co., Ltd.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.